Literature DB >> 11071881

Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil.

U Pandya1, S K Srivastava, S S Singhal, A Pal, S Awasthi, P Zimniak, Y C Awasthi, S V Singh.   

Abstract

Clinical efficacy of alkylating anticancer drugs, such as chlorambucil, is often limited by the emergence of drug resistant tumor cells. Increased glutathione (GSH) conjugation (inactivation) of alkylating anticancer drugs or their activated metabolites due to overexpression of the Pi class GSH S-transferase (hGSTP1-1) is believed to be an important mechanism in tumor cell resistance to alkylating agents. Interestingly, the hGSTP1 locus is polymorphic in human populations and involves amino acid residues in positions 104 (isoleucine or valine) and/or 113 (alanine or valine). Here, we report that the allelic variants of hGSTP1-1 significantly differ in their efficiency in catalyzing the GSH conjugation of chlorambucil. Catalytic efficiency of the hGSTP1-1(I104,A113) isoform toward chlorambucil was approximately 2.5-, 7.5- and 15-fold higher compared with I104,V113, V104,A113 and V104,V113 variants of hGSTP1-1, respectively. The results of the present study suggest that hGSTP1-1 polymorphism may be an important factor in GST-mediated tumor cell resistance to some alkylating agents. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071881     DOI: 10.1006/bbrc.2000.3787

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Association study of SNPs of genes IFNGR1 (rs137854905), GSTT1 (rs71748309), and GSTP1 (rs1695) in gastric cancer development in samples of patient in the northern and northeastern Brazil.

Authors:  Rubistenia Miranda Soares de Araújo; Cynthia Farias Vieira de Melo; Fidelis Manes Neto; Juarez Nóbrega da Silva; Leonardo Ferreira Soares; Marilia de Arruda Cardoso Smith; Edilson Carvalho Sousa; Rommel Mario Rodríguez Burbano; Arnaldo Correia de Medeiros; Eleonidas Moura Lima
Journal:  Tumour Biol       Date:  2014-01-23

Review 2.  Glutathione and redox signaling in substance abuse.

Authors:  Joachim D Uys; Patrick J Mulholland; Danyelle M Townsend
Journal:  Biomed Pharmacother       Date:  2014-06-24       Impact factor: 6.529

3.  Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.

Authors:  Lindsay Kilburn; M Fatih Okcu; Tao Wang; Yumei Cao; Amy Renfro-Spelman; Kenneth D Aldape; Mark R Gilbert; Melissa Bondy
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

Review 4.  Racial disparities, cancer and response to oxidative stress.

Authors:  Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew
Journal:  Adv Cancer Res       Date:  2019-04-23       Impact factor: 6.242

5.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  Common polymorphisms in CYP1A1, GSTM1, GSTT1, GSTP1 and XPD genes and endogenous DNA damage.

Authors:  Marta Wlodarczyk; Grazyna Nowicka
Journal:  Mol Biol Rep       Date:  2011-12-20       Impact factor: 2.316

7.  Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.

Authors:  Shilong Zhong; Min Huang; Xiuyan Yang; Liuqin Liang; Yixi Wang; Marjorie Romkes; Wei Duan; Eli Chan; Shu-Feng Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

8.  Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Authors:  Zdenek Kala; Jiří Dolina; Filip Marek; Lydie Izakovicova Holla
Journal:  J Hum Genet       Date:  2007-05-03       Impact factor: 3.172

Review 9.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

Review 10.  Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.

Authors:  L M Bull; D L White; M Bray; Z Nurgalieva; H B El-Serag
Journal:  Dis Esophagus       Date:  2009-02-13       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.